Incannex Healthcare (IXHL) Research & Development (2022 - 2026)

Incannex Healthcare (IXHL) has reported Research & Development for 5 consecutive years, with $321000.0 the latest figure, recorded in Q1 2026.

• Quarterly Research & Development fell 88.26% year-over-year to $321000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 million (down 34.91% YoY) and the FY2025 annual result came in at $10.7 million, down 16.55% from the prior year.
• Research & Development slipped to $321000.0 in Q1 2026 per IXHL's latest filing, from $2.3 million in the prior quarter.
• Over the last five years, Research & Development for IXHL reached as high as $4.4 million in Q2 2024 and fell as low as $321000.0 in Q1 2026.
• A 5-year average of $2.3 million and a median of $2.4 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development jumped 154.61% — and 2026, when it plunged 88.26%.
• Year by year, Research & Development stood at $1.5 million in 2022, then surged by 70.3% to $2.6 million in 2023, then plunged by 46.4% to $1.4 million in 2024, then soared by 61.24% to $2.3 million in 2025, then slumped by 85.92% to $321000.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $321000.0, $2.3 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.